Skip to content
value.today

Bluebird Bio, Inc.

BLUEUnlisted company
$279 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$84 M
For year ending December-2024
Net income
$-241 M
-287.2% margin
SEC filing
Employees
518
As on 2021
value.today research

Bluebird Bio, Inc. in brief

Bluebird Bio, Inc. is an unlisted company in the Biotechnology industry, based in Somerville, Massachusetts, USA. It was founded in 1992. In the year to December 2024 it had sales of $84 M and a net loss of $241 M. It employs about 518 people.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Bluebird Bio, Inc.

Genetix Biotherapeutics (previously bluebird bio, Inc.) based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company is owned by investment funds managed by The Carlyle Group and SK Capital Partners.

One of the company's approved drugs is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.

The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Bluebird Bio, Inc. timeline

5 events, 1992–2024
  1. 1992
  2. 🏁
    Founded
  3. 2004
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2010
  6. ✎
    Renamed bluebird bio, Inc.
    Formerly Genetix Pharmaceuticals Inc.
  7. 2013
  8. 🔔
    · approximate
    Initial public offering on Nasdaq as BLUE
  9. 2024
  10. 💰
    Record revenue of $84 million
    FY2024, the highest of the 6 years on record.

Events of Bluebird Bio, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Bluebird Bio, Inc.

Acquisitions and changes
Taken over: the company reported a change in control and the delisting of its shares to the SEC on 2 June 2025 (Form 8-K).

Market cap history

$0 M$1.3 B$2.6 B$3.9 B$5.2 B20202021202220232024

World rank over time

▼ down 13,430 places since 2020
2020-01-01: #2766#2,76620202021-01-01: #4414#4,41420212022-01-07: #11640#11,64020222022-12-25: #11315#11,31520222023-07-30: #13844#13,84420232024-01-05: #16196#16,1962024

Rank in USA: #904 (Jan 2020) · #1,389 (Jan 2021) · #2,938 (Jan 2022) · #2,447 (Dec 2022) · #2,850 (Jul 2023) · #2,994 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-192.4%
Operating margin
-322.7%
Return on equity
—
Liabilities / assets
106.9%
Revenue growth
+184.1%
R&D / revenue
112.5%
Revenue per employee
$162 K
Profit per employee
$-465 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $35M, net income $-336M$35MFY17Fiscal year ending Dec 2018: revenue $55M, net income $-556M$55MFY18Fiscal year ending Dec 2019: revenue $45M, net income $-790M$45MFY19Fiscal year ending Dec 2020: revenue —, net income $-619M—FY20Fiscal year ending Dec 2021: revenue $4M, net income $-819M$4MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-230M$4MFY22Fiscal year ending Dec 2023: revenue $30M, net income $-212M$30MFY23Fiscal year ending Dec 2024: revenue $84M, net income $-241M$84MFY24
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2024$84M+184.1%$-270M$-241M-287.2%
Dec 2023$30M+719.4%$-244M$-212M-718.3%
Dec 2022$4M-1.6%$-250M$-230M-6398.3%
Dec 2021$4M—$-591M$-819M-22387.4%
Dec 2020——$-559M$-619M—
Dec 2019$45M-18.2%$-563M$-790M-1767.7%
Dec 2018$55M+54.1%$-572M$-556M-1018.0%
Dec 2017$35M—$-332M$-336M-947.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2024$-260M$3M$-263M$-24.84—
Dec 2023$-235M$4M$-239M$-38.59—
Dec 2022$-316M$8M$-324M$-2.93—
Dec 2021$-636M$15M$-650M$-11.89—
Dec 2020$-470M$29M$-499M$-9.95—
Dec 2019$-564M$71M$-635M$-14.31—
Dec 2018$-413M$56M$-469M$-10.68—
Dec 2017$-281M$62M$-343M$-7.71—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$104M
Net income, trailing 12 months
$-200M
RevenueNet income
Three months to Jun 2023: revenue $7M, net income $-63M$7MJun ’23Three months to Sep 2023: revenue $12M, net income $-87M$12MSep ’23Three months to Dec 2023 (from the annual report): revenue $8M, net income $-81M$8MDec ’23Three months to Mar 2024: revenue $19M, net income $-70M$19MMar ’24Three months to Jun 2024: revenue $16M, net income $-81M$16MJun ’24Three months to Sep 2024: revenue $11M, net income $-61M$11MSep ’24Three months to Dec 2024 (from the annual report): revenue $39M, net income $-29M$39MDec ’24Three months to Mar 2025: revenue $39M, net income $-29M$39MMar ’25

Latest quarter to Mar 2025: revenue $39M (+108.5% on a year earlier), net income $-29M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Mar 2025.

SEC filings

Official filings of Bluebird Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$84 M
Operating income
$-270 M
Net income
$-241 M

For year ending December-2024 · source: SEC filing

Balance sheet

Total assets
$460 M
Total liabilities
$492 M
Total equity
$-32 M

As of December-2024

Insider trading at Bluebird Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
51
since
-$27 K$0Nov 2023: bought $0 (0 trades), sold $10 K (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $20 K (1 trades)Jan 2024: bought $0 (0 trades), sold $5 K (2 trades)Jan 24Feb 2024: bought $0 (0 trades), sold $9 K (3 trades)Mar 2024: bought $0 (0 trades), sold $27 K (3 trades)MarJun 2024: bought $0 (0 trades), sold $4 K (1 trades)Sep 2024: bought $0 (0 trades), sold $19 K (2 trades)SepDec 2024: bought $0 (0 trades), sold $2 K (2 trades)Jan 2025: bought $0 (0 trades), sold $1 K (2 trades)Jan 25Feb 2025: bought $0 (0 trades), sold $4 K (4 trades)Mar 2025: bought $0 (0 trades), sold $8 K (3 trades)Mar
Bought (open market)Sold (open market)Hover a month for the totals
Bluebird Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed O. James SterlingChief Financial OfficerDisposal to the company-5,000——0Form 4
filed Michael CloonanDirectorDisposal to the company-1,867——0Form 4
filed Richard A. ColvinChief Medical OfficerDisposal to the company-4,166——0Form 4
filed Najoh Tita-ReidDirectorDisposal to the company-1,245——0Form 4
filed O. James SterlingChief Financial OfficerGrant or award+2,500——2,500Form 4
filed Andrew ObenshainPresident and CEO, DirectorDisposal to the company-9,300——0Form 4
filed Elisabeth LeidermanDirectorDisposal to the company-1,245——0Form 4
filed Mark VachonDirectorDisposal to the company-1,245——0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Bluebird Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 1-for-20 reverse split

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Bluebird Bio, Inc. scorecard#

Passes 5 of the 12 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 4). Fiscal year 2024.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth4 of 5
    • ✓Revenue grew in the newest year184.1%Revenue up 184.1% in fiscal 2024.
    • ✓Revenue up more than 5% a year over three years184.0%184.0% a year over the three years to fiscal 2024.
    • ✓Faster growth over three years than its peers' median184.0%184.0% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-24.84 vs -38.59Diluted EPS -24.84 in fiscal 2024 against -38.59 the year before (report's currency).
    • ✓Net income higher than five years earlier-$241 M-$241 M in fiscal 2024 against -$790 M in 2019.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$241 MNet income -$241 M in fiscal 2024.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2024.
    • ✗Operating margin above its peers' median-322.7%-322.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-322.7%-322.7% in fiscal 2024 against -16145.1% in 2021.
  • Financial health0 of 2
    • ✗Short-term assets cover short-term liabilities0.5×Current ratio 0.48 at the end of fiscal 2024.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2024.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year76.5%Diluted shares up 76.5% in fiscal 2024.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2024#

Worked out from Bluebird Bio, Inc.'s statements, beside the median of Biotechnology.

Bluebird Bio, Inc.: main financial ratios in 2024
Ratio2024Median of peers
Operating margin-322.7%-60.5%
Net margin-287.2%-68.9%
Revenue growth, 3 years a year184.0%12.9%
Revenue growth184.1%15.8%
Free cash flow margin-313.4%-61.5%

2of 8on the Piotroski tests of financial strength

  • Net loss of $241 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$263 million.
  • The share count rose 76.5% in the year.
  • Shareholders' equity is negative: -$32 million.

Bluebird Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Bluebird Bio, Inc.: statements by fiscal year
PeriodTrendFY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015
Income statement
Revenue84293.63.70r4555356.214
Cost of revenue893410—5.43.00.91.5——
Gross profit−5.6−4.0−6.5———————
Research and development94168200r320319r327r449273205134
Selling, general and administrative168166140r210240r236r17494——
General and administrative——————174946546
Operating expenses——————627368274183
Total costs and expenses265333346r595559r563r627368——
Operating income−270−244−250r−591−559r−563r−572−332−268−169
Interest and finance income8.29.91.0———————
Interest expense and finance costs23166.3———————
Other non-operating income (expense)443925r28−6.9r−10.0r2.0−1.3−0.1r2.3
Income before tax——−266−562−560r−556r−555−335−264−167
Income tax0.1−0.10.10.30.7−0.50.20.2−0.60.1
Income from continuing operations−241−212−267−563−561−555————
Income from discontinued operations——0−257−58−235————
Net income including minority interests—————−790−556−336−264—
Net income attributable to shareholders−241−212−230r−819−619−790−556−336−264−167
Earnings per share, basic-24.84-38.59r-2.93r-11.89-9.95-14.31-10.68-7.71-7.07-4.81
Earnings per share, diluted-24.84-38.59r-2.93r-11.89-9.95-14.31-10.68-7.71-7.07-4.81
Shares, weighted average (basic)9.75.5r796962—————
Shares, weighted average (diluted)9.75.5r7969625552443735
Balance sheet
Cash and cash equivalents62222113161261r327403759279164
Short-term investments—067138420r779983532425354
Receivables——0————4.6——
Inventory65230011—————
Other current assets——11—————3.1r6.0
Current assets155282204r3371,2161,1521,4191,323724524
Property, plant and equipment61669.49.717r15124720015783
Right-of-use (leased) assets177201231r9268r186————
Goodwill5.65.65.65.65.6r1313131313
Other intangible assets9.5104.904.4r1413172124
Total assets460619570r5941,7811,7272,2431,9011,1181,002
Accounts payable341815r2614r431813146.3
Debt due within a year720————————
Current liabilities321200157r153204224146967540
Lease liabilities (non-current)162187209r6656r171————
Total liabilities492425435r220426442358277249152
Retained earnings−4,501−4,260−4,048r−3,720−2,901−2,282−1,499−914−578−314
Shareholders' equity−32195134r276r1,3551,2851,8851,623869850
Total liabilities and equity460619570r5941,7811,7272,2431,9011,1181,002
Shares outstanding9.79.6r837166555549r4137
Cash-flow statement
Depreciation and amortization60288.2r4.95.1r4.1r139.85.93.7
Share-based compensation141935r128157161111534041
Cash from operating activities−260−235−316r−636−470−564−413−281−190−98
Capital expenditure−2.6−4.2−8.2−15−29−71−56−62−28r−7.1
Intangible assets bought0−4.9−5.0−8.50−5.200——
Cash from investing activities3.9155250563−84508−679−317r67r−572
Debt issued710————————
Shares issued024854——06491,007r235r10
Cash from financing activities8719618r−94547217381,076242487
Change in cash−169116−48−167−8.0−35−355479r119r−184
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Bluebird Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Financial statements withdrawnFiling

Delisting notice 3 · Financial statements withdrawn 1 · Restructuring 1 · Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 4 · Material agreement 12 · Agreement ended 1 · New debt 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 2 · Results announced 6

Bluebird Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed8-K
Material agreement8-K
Material agreement8-K
Agreement ended8-K
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Directors and officersShareholder vote8-K
Delisting notice8-K
Restructuring8-K
Material agreement8-K
Material agreement8-K
Delisting notice8-K
Material agreementNew debtResults announced8-K
Material agreement8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Delisting notice8-K
Financial statements withdrawnResults announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Material agreement8-K
Material agreementNew debtBylaws or fiscal year changed8-K
Results announced8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jun 2, 2025

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Bluebird Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$75 MNo. 4$50 to $250 million2equitySEC
Jul 2012$60 MNo. 3$50 to $250 million17equitySEC
Apr 2011$15 MNo. 2$10 to $50 million5equitySEC
Mar 2010$38 MNo. 1$10 to $50 million5equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Bluebird Bio, Inc.#

$120 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid and health issues.

Lobbying, 2025
$120 K
#1,190 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
—
  • Medicare/Medicaid2 reports
  • Health Issues2 reports

Lobbying firms hired in 2025

Arnold & Porter Kaye Scholer LLP $120 K

Bluebird Bio, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2025$120 K—2
2024$420 K$300 K6
2023$370 K$370 K7
2022$120 K$120 K6
2021$580 K$440 K14
2020$780 K$780 K20
2019$600 K$420 K14
2018$290 K—8

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “bluebird bio”, “bluebird bio, Inc.” and “Bluebird Bio”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Bluebird Bio, Inc.#

3 labor condition applications certified in fiscal 2026 for 3 positions, at a median wage of $170 K a year.

Certified, FY2026
3
#1,351 among companies on value.today
Worker positions
3
Median wage offered
$170 K
a year, full-time
Applications filed
3
Bluebird Bio, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Associate Director, Pharmacovigilance-Medical AffairsRegulatory Affairs Specialists1$170 K
Director, Translational BiomarkersMolecular and Cellular Biologists1$205 K
Senior ScientistMolecular and Cellular Biologists1$144 K

Where: Somerville, MA 3

Bluebird Bio, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202633$170 K3
FY202544$137 K4
FY202499$165 K9
FY20231515$110 K16
FY20222424$131 K27
FY20213752$120 K41
FY20203961$125 K43

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as BLUEBIRD BIO, INC.

Layoffs at Bluebird Bio, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2024
Latest
—
2024-09-23
Bluebird Bio, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2022············—
Bluebird Bio, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
25% of workforceRestructuring planSEC 8-K“The Restructuring includes a reduction of the Company’s workforce by approximately 25% of its headcount.”Filing
30% of workforceRestructuring planSEC 8-K“As part of the restructuring, bluebird plans to reduce its workforce by approximately 30% across the second and third quarters of 2022.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Bluebird Bio, Inc. compares in Biotechnology

  • Revenue$84 M · higher than 67% of 647
  • Net margin-192.4% · higher than 29% of 408
  • Revenue growth184.1% · higher than 89% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Bluebird Bio, Inc.🇺🇸$279 M—-192.4%+184.1%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2024
Balance sheet:
As of December-2024
Employees:
As on 2021
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, Wikidata, Wikipedia; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Bluebird Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Bluebird Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Bluebird Bio, Inc.? Suggest a correction